Actively Recruiting
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Led by Cybrexa Therapeutics · Updated on 2025-10-06
40
Participants Needed
17
Research Sites
53 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
CONDITIONS
Official Title
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female subjects with histologically or cytologically confirmed high-grade serous cancer of the ovary, fallopian tube, or primary peritoneum
- Disease must be refractory to prior therapy and platinum-resistant, defined as progression during or within 26 weeks after platinum-based chemotherapy
- Subjects may have received only 1 platinum-based chemotherapy regimen of at least 4 cycles or progressed after a second platinum regimen
- Up to 2 additional systemic regimens allowed for advanced/metastatic disease; maintenance therapies like PARP inhibitors or bevacizumab do not count
- Age 18 years or older at signing informed consent
- Measurable disease per RECIST 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate liver, kidney, hematologic, lung, and coagulation function
You will not qualify if you...
- Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks before the first dose of CBX-12
- Currently receiving any other anticancer or investigational agents
- Clinically significant intercurrent disease
- Active human immunodeficiency virus (HIV) infection
- Active hepatitis B or C infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 17 locations
1
Honor Health
Scottsdale, Arizona, United States, 85260
Withdrawn
2
Arizona Oncology Associates
Tucson, Arizona, United States, 85711
Active, Not Recruiting
3
Usc Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Active, Not Recruiting
4
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
Active, Not Recruiting
5
D&H Cancer Research Center
Margate, Florida, United States, 33063
Active, Not Recruiting
6
South Florida Gynecology
Tampa, Florida, United States, 33606
Active, Not Recruiting
7
Northwest Cancer Centers
Dyer, Indiana, United States, 46311
Withdrawn
8
Norton Cancer Institute
Louisville, Kentucky, United States, 40202
Active, Not Recruiting
9
Women's Cancer Care
Covington, Louisiana, United States, 70433
Active, Not Recruiting
10
Pci Nyu Langone Health
New York, New York, United States, 10016
Active, Not Recruiting
11
Albert Einstein College of Medicine Montefiore Medical
New York, New York, United States, 10021
Active, Not Recruiting
12
University Hospitals Seidman Cancer Center
Cleveland, Ohio, United States, 44106
Active, Not Recruiting
13
Oncology Associates of Oregon
Eugene, Oregon, United States, 97401
Active, Not Recruiting
14
Allegheny Singer Research Institute D/B/A Ahn Research Institution
Pittsburgh, Pennsylvania, United States, 15212
Actively Recruiting
15
Mary Crowley Cancer Research
Dallas, Texas, United States, 75251
Actively Recruiting
16
Texas Oncology- Gulf Coast
The Woodlands, Texas, United States, 77380
Active, Not Recruiting
17
Multicare Institute For Research & Innovation
Tacoma, Washington, United States, 98405
Active, Not Recruiting
Research Team
C
Clinical Operations Trial Team
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here